SCHEMBL16612648

SCHEMBL16612648

CC1(C)[C@@H]2C[C@H]1C(C=Cc1ccccc1)=CC2=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 1/20 0.39
KDM1A O60341 3/20 0.37
BUB1 O43683 1/20 0.36
MAPT P10636 4/20 0.35
ALDH1A1 P00352 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MAOA P21397 1/20 0.35
CYP1A2 P05177 1/20 0.35
HIF1A Q16665 1/20 0.35
BRD4 O60885 2/20 0.35
CREBBP Q92793 2/20 0.35
SRD5A1 P18405 3/20 0.35
SRD5A2 P31213 3/20 0.35
LMNA P02545 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23931226 1.00 CYP2C19 (0.39) CYP2C19CYP3A4CYP2D6KDM1ABUB1
SCHEMBL6544986 1.00 CYP2C19 (0.39) CYP2C19CYP3A4CYP2D6KDM1ABUB1
SCHEMBL23931227 1.00 CYP2C19 (0.39) CYP2C19CYP3A4CYP2D6KDM1ABUB1
SCHEMBL16612646 1.00 CYP2C19 (0.39) CYP2C19CYP3A4CYP2D6KDM1ABUB1
SCHEMBL23931228 1.00 CYP2C19 (0.39) CYP2C19CYP3A4CYP2D6KDM1ABUB1
SCHEMBL16612574 0.92 NPC1 (0.35) CYP2C19CYP3A4CYP2D6BUB1ALDH1A1
SCHEMBL30284627 0.92 NPC1 (0.35) CYP2C19CYP3A4CYP2D6BUB1ALDH1A1
SCHEMBL16612575 0.92 NPC1 (0.35) CYP2C19CYP3A4CYP2D6BUB1ALDH1A1
SCHEMBL23931235 0.85 APP (0.36) CYP2C19CYP3A4CYP2D6KDM1AMAPT
SCHEMBL23931237 0.85 APP (0.36) CYP2C19CYP3A4CYP2D6KDM1AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240415787-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2024-12-19 US claimed
EP-4397304-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES Shin Poong Pharmaceutical Co., Ltd. (KR) 2024-07-10 EP claimed
CN-117897145-A Composition for treating or preventing obesity or obesity-related liver diseases comprising verbenone derivatives 韩国新丰制药株式会社 2024-04-16 CN claimed
WO-2023033517-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES 신풍제약주식회사 2023-03-09 WO claimed
US-10710951-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-07-14 US claimed
EP-2857007-B1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE UNIV KOREA RES & BUS FOUND (KR) 2018-03-28 EP claimed
US-20170166505-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-15 US claimed
US-9603842-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2017-03-28 US claimed
US-20150148362-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2015-05-28 US claimed
EP-2857007-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE Korea University Research and Business Foundation (KR) 2015-04-08 EP claimed
US-20240415787-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2024-12-19 US disclosed
EP-4397304-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES Shin Poong Pharmaceutical Co., Ltd. (KR) 2024-07-10 EP disclosed
CN-117897145-A Composition for treating or preventing obesity or obesity-related liver diseases comprising verbenone derivatives 韩国新丰制药株式会社 2024-04-16 CN disclosed
WO-2023033517-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES 신풍제약주식회사 2023-03-09 WO disclosed
US-10710951-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-07-14 US disclosed
EP-2857007-B1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE UNIV KOREA RES & BUS FOUND (KR) 2018-03-28 EP disclosed
US-20170166505-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-15 US disclosed
US-9603842-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2017-03-28 US disclosed
US-20150148362-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2015-05-28 US disclosed
EP-2857007-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE Korea University Research and Business Foundation (KR) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166505-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE CASP3, DCX, BAX CYP2C19 1307/4885CYP3A4 1673/4885CYP2D6 2317/4885
US-10710951-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease CASP3, DCX, BAX CYP2C19 1307/4885CYP3A4 1673/4885CYP2D6 2317/4885
US-20240415787-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES SMAD3, TGFB1, TGFB2 CYP2C19 2846/4885CYP3A4 1452/4885CYP2D6 3833/4885
US-20150148362-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE CASP3, DCX, BAX CYP2C19 1307/4885CYP3A4 1673/4885CYP2D6 2317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.